Stephen Simpson
Stephen Simpson
Stop FollowingStephen Simpson
View as an RSS Feed
View Stephen Simpson's Articles BY TICKER:
A,
ABB,
ABT,
ACHN,
ACI,
ADI,
ADTN,
AEP,
AES,
AET,
AEZS,
AGCO,
AIMC,
ALGN,
ALKS,
ALNY,
ALPMY.PK,
ALU,
ALXN,
AME,
AMED,
AMGN,
AMRN,
AMX,
ANFI,
ANGO,
APNHY.PK,
ARAY,
ARCO,
ARIA,
ARQL,
ASOMY.PK,
ATHN,
ATLKY.PK,
ATRC,
AUXL,
AVD,
AVGO,
AZN,
BA,
BABY,
BAC,
BAX,
BBT,
BCR,
BDX,
BIIB,
BIOD,
BMRN,
BMTI,
BMY,
BP,
BRCD,
BRFS,
BRK.B,
BSFT,
BSX,
BTU,
C,
CAT,
CBD,
CBST,
CELG,
CFN,
CFX,
CHKP,
CJES,
CLDX,
CMA,
CMI,
CNH,
COO,
COP,
COV,
CPHD,
CR,
CSCO,
CSII,
CVGI,
CVV,
CVX,
CYCC,
DD,
DE,
DHR,
DIS,
DNDN,
DUSA,
EAC,
ELGX,
ELN,
EMR,
ENDP,
ET,
ETN,
ETRM,
EVAC,
EW,
EXAS,
EXEL,
FAST,
FCFS,
FCX,
FET,
FF,
FFIV,
FHN,
FIRE,
FMX,
FOLD,
FRCOY.PK,
FRX,
FSII,
FUL,
GBX,
GE,
GILD,
GLEKY.PK,
GLPW,
GLW,
GMAN,
GMED,
GNRC,
GPRO,
GRC,
GSK,
GTLS,
GTOMY.PK,
GTXI,
HAL,
HLF,
HLUYY.PK,
HNZ,
HOCPY.PK,
HOGS,
HOLI,
HOLX,
HON,
HRC,
HRL,
HSP,
HTWR,
HURC,
HW,
HYPMY.PK,
IART,
ICUI,
IDIX,
IIVI,
ILMN,
IMGN,
INGIY.PK,
IR,
ISRG,
ISTA,
ITW,
JCI,
JNJ,
JOY,
JPM,
K,
KDN,
KMTUY.PK,
KOP,
KRFT,
LABL,
LAWS,
LECO,
LHCG,
LIFE,
LLY,
LMNX,
LNCR,
LPDX,
LSI,
LXRX,
MAKO,
MASI,
MCD,
MDCI,
MDLZ,
MDT,
MDVN,
MEAS,
MMM,
MNTX,
MON,
MR,
MRK,
MSCC,
MSFT,
MSM,
MTB,
MTL,
MTNOY.PK,
MTRX,
MTW,
MYL,
NAV,
NBHGY.PK,
NBIX,
NGVC,
NKTR,
NOK,
NPO,
NPSP,
NUACF.PK,
NUVA,
NVDQ,
NVO,
NVS,
ODFL,
OMER,
OSK,
OZRK,
PAA,
PAY,
PB,
PCXCQ.OB,
PEP,
PFE,
PG,
PH,
PLL,
PMTI,
PNC,
POT,
PRAA,
PRIM,
PRX,
PVD,
PWAV,
QCOR,
QSFT,
RAVN,
RDWR,
RHHBY.OB,
RIG,
RIGL,
SANW,
SASR,
SBMRY.PK,
SCGLY.PK,
SGEN,
SHPG,
SHS,
SI,
SKH,
SLTM,
SLXP,
SNCR,
SNHY,
SNMX,
SNV,
SNY,
SPLK,
SPNC,
SPW,
SSH,
STB,
STJ,
STLD,
SUMR,
SWI,
SWK,
SYK,
TC,
TEAR,
TECH,
TEN,
TEVA,
TEX,
TKC,
TNGO,
TRCR,
TRGT,
TRUMY.PK,
TSRX,
TWGP,
TWI,
TYPE,
UNH,
UPI,
USB,
UTEK,
UTX,
V,
VICL,
VMW,
VOLC,
VVUS,
WFT,
WLP,
X,
XLNX,
XNPT,
XOM,
XPO,
XRAY,
XYL,
YMI,
ZION,
ZIOP,
ZMH,
ZOLL
- Caterpillars, Deer(E)s, And CNH - Oh My
- If GTX Can Finally Catch A Break, The Rewards Look Worthwhile
- Challenging Targets Could Pay Off For Ziopharm Oncology
- Should Seattle Genetics Start Thinking More Like A Pharma Company?
- Is AEterna Zentaris Really Worth All This Fuss?
- A Med-Tech Shopping List For Japanese Companies
- Zoll Medical: One Of The Best Growth Stories Is Gone
- Earnings Recap: Hurco's Results Surpass Estimates
- Approaching The End Of The Quest
- Pall Has The Quality, But Valuation Is A Stretch
- MAKO Surgical: Growth Investors Should Buy On Pullback
- Exact Sciences Could Be Exactly What Biotech Investors Need
- Primoris Services' Pipeline To Stronger Growth
- Can Transcend Services Write Its Own Ticket?
- AFP Provida: A Very Different Dividend Play
- Ongoing Execution Inconsistency Clouds Brocade's Prospects
- Sauer-Danfoss Pummeled, But Not KO'ed
- Despite Setback, BB&T Has Plenty Of Growth Opportunities
- Chart Industries Running Hot And Cold
- What's It Going To Take To Get Salix Cheap?
- Tower Group's Earnings: See The Value, Hope For The Execution?
- AES: Above Average Growth, An Improving Balance Sheet, Higher Dividends
-
Do Boeing Investors Need To Worry About The Order Book?
- Endo Pharmaceuticals Playing An Unconventional Hand
- Vivus's Qnexa And Its Potential Value
- Volcano Still Searching For The Sweet Spot
- NuVasive Has Been Bloodied, But The Growth Story Isn't Broken
-
Can Altra Holdings Become A Clutch Performer?
- J&J CEO Switch Is A Necessary Step Forward
- Mylan Looks To Reap A Harvest Of Patent Expirations
- Medtronic's Growth Problems Still Front And Center
- Can Much-Maligned Mechel Outperform?
